Strong demand for Roche’s specialty cancer medicines, many of which are bought privately in emerging markets, has helped it defy an expected slowdown in sales in China following a crackdown on sales practices there. The Swiss group on Thursday posted an 8 percent rise in third-quarter sales in local currencies - or 2.7 percent in Swiss francs, after adverse foreign exchange moves - helped by strong uptake of two new breast cancer drugs. The world’s largest maker of cancer drugs chalked up growth of 12 percent in the United States in the first nine months of the year and said it had seen continued strong growth in China, where sales were up 23 percent.
Help employers find you! Check out all the jobs and post your resume.
